CA2467245A1 - Prevention of flap necrosis in plastic surgery - Google Patents
Prevention of flap necrosis in plastic surgery Download PDFInfo
- Publication number
- CA2467245A1 CA2467245A1 CA002467245A CA2467245A CA2467245A1 CA 2467245 A1 CA2467245 A1 CA 2467245A1 CA 002467245 A CA002467245 A CA 002467245A CA 2467245 A CA2467245 A CA 2467245A CA 2467245 A1 CA2467245 A1 CA 2467245A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- cyclodextrin
- pedicle
- topically
- nitrosylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000017074 necrotic cell death Effects 0.000 title claims abstract description 7
- 238000002316 cosmetic surgery Methods 0.000 title description 2
- 230000002265 prevention Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 25
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004194 lidocaine Drugs 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000002840 nitric oxide donor Substances 0.000 claims abstract description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 11
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 10
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940002612 prodrug Drugs 0.000 claims abstract description 8
- 239000000651 prodrug Substances 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 6
- 238000001356 surgical procedure Methods 0.000 claims abstract description 6
- 230000036770 blood supply Effects 0.000 claims abstract description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- QQZWEECEMNQSTG-UHFFFAOYSA-N Ethyl nitrite Chemical group CCON=O QQZWEECEMNQSTG-UHFFFAOYSA-N 0.000 claims description 7
- 229940124549 vasodilator Drugs 0.000 claims description 7
- 239000003071 vasodilator agent Substances 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- -1 alkyl nitrite Chemical compound 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 238000012377 drug delivery Methods 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 14
- 239000000499 gel Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 210000003462 vein Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 206010047139 Vasoconstriction Diseases 0.000 description 8
- 230000025033 vasoconstriction Effects 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000004006 C-nitroso compounds Chemical group 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 150000004007 S-nitroso compounds Chemical group 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003633 blood substitute Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 238000002406 microsurgery Methods 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- QWPCKAAAWDCDCW-VKHMYHEASA-N (2s)-2-amino-4-nitrososulfanylbutanoic acid Chemical compound OC(=O)[C@@H](N)CCSN=O QWPCKAAAWDCDCW-VKHMYHEASA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 241001440267 Cyclodes Species 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 229940124135 Factor VIII inhibitor Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 150000004009 O-nitroso compounds Chemical group 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010001742 S-Nitrosoglutathione Proteins 0.000 description 1
- XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 description 1
- UOHAKHBEJRPHQZ-VKHMYHEASA-N S-nitroso-L-cysteinylglycine Chemical compound O=NSC[C@H](N)C(=O)NCC(O)=O UOHAKHBEJRPHQZ-VKHMYHEASA-N 0.000 description 1
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 1
- 108010093594 S-nitrosoalbumin Proteins 0.000 description 1
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 210000002815 epigastric artery Anatomy 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- IDNUEBSJWINEMI-UHFFFAOYSA-N ethyl nitrate Chemical compound CCO[N+]([O-])=O IDNUEBSJWINEMI-UHFFFAOYSA-N 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 238000010865 video microscopy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33617501P | 2001-12-06 | 2001-12-06 | |
| US60/336,175 | 2001-12-06 | ||
| PCT/US2002/036138 WO2003049593A2 (en) | 2001-12-06 | 2002-12-02 | Prevention of flap necrosis in plastic surgery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2467245A1 true CA2467245A1 (en) | 2003-06-19 |
Family
ID=23314894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002467245A Abandoned CA2467245A1 (en) | 2001-12-06 | 2002-12-02 | Prevention of flap necrosis in plastic surgery |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060153931A1 (enExample) |
| EP (1) | EP1463440B1 (enExample) |
| JP (2) | JP4563679B2 (enExample) |
| AT (1) | ATE450187T1 (enExample) |
| AU (1) | AU2002365036B2 (enExample) |
| CA (1) | CA2467245A1 (enExample) |
| DE (1) | DE60234642D1 (enExample) |
| WO (1) | WO2003049593A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005235308B2 (en) | 2004-04-19 | 2011-12-01 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| WO2010151241A1 (en) | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
| US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| WO2010151240A1 (en) | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| DK2658551T3 (da) | 2010-12-29 | 2020-09-21 | Strategic Science & Tech Llc | Behandling af erektil dysfunktion og andre indikationer |
| CN105878172A (zh) | 2010-12-29 | 2016-08-24 | 战略科学与技术有限责任公司 | 治疗变态反应和其它适应症的系统和方法 |
| WO2020185674A1 (en) * | 2019-03-08 | 2020-09-17 | South Dakota Board Of Regents | A vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing |
| CN112843241B (zh) * | 2021-01-14 | 2023-07-25 | 中国药科大学 | 可生物响应的一氧化氮供体型聚合物前药及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5300302A (en) * | 1990-10-04 | 1994-04-05 | Nestec S.A. | Pharmaceutical composition in gel form in a dispensing package |
| JP2599031B2 (ja) * | 1990-11-30 | 1997-04-09 | 宇部興産株式会社 | 高純度亜硝酸アルキルエステルの製造法 |
| ES2092460T3 (es) * | 1994-05-27 | 2001-02-01 | Cellegy Pharma Inc | Composicion dadora de oxido nitrico para el tratamiento de trastornos anales. |
| US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US5770645A (en) * | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US5797887A (en) * | 1996-08-27 | 1998-08-25 | Novovasc Llc | Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation |
| WO1998050430A2 (en) * | 1997-05-02 | 1998-11-12 | Somatogen, Inc. | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging |
| AU764921B2 (en) * | 1998-12-14 | 2003-09-04 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
| AU3490300A (en) * | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| US6359182B1 (en) * | 2000-10-26 | 2002-03-19 | Duke University | C-nitroso compounds and use thereof |
-
2002
- 2002-12-02 WO PCT/US2002/036138 patent/WO2003049593A2/en not_active Ceased
- 2002-12-02 EP EP02804687A patent/EP1463440B1/en not_active Expired - Lifetime
- 2002-12-02 AU AU2002365036A patent/AU2002365036B2/en not_active Ceased
- 2002-12-02 AT AT02804687T patent/ATE450187T1/de not_active IP Right Cessation
- 2002-12-02 US US10/521,394 patent/US20060153931A1/en not_active Abandoned
- 2002-12-02 DE DE60234642T patent/DE60234642D1/de not_active Expired - Lifetime
- 2002-12-02 CA CA002467245A patent/CA2467245A1/en not_active Abandoned
- 2002-12-02 JP JP2003550646A patent/JP4563679B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-03 JP JP2009275959A patent/JP5266191B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002365036A1 (en) | 2003-06-23 |
| WO2003049593A2 (en) | 2003-06-19 |
| EP1463440A2 (en) | 2004-10-06 |
| AU2002365036B2 (en) | 2006-09-21 |
| EP1463440A4 (en) | 2008-01-23 |
| EP1463440B1 (en) | 2009-12-02 |
| US20060153931A1 (en) | 2006-07-13 |
| JP4563679B2 (ja) | 2010-10-13 |
| JP5266191B2 (ja) | 2013-08-21 |
| JP2005511708A (ja) | 2005-04-28 |
| DE60234642D1 (de) | 2010-01-14 |
| WO2003049593A3 (en) | 2004-02-19 |
| ATE450187T1 (de) | 2009-12-15 |
| JP2010047619A (ja) | 2010-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5266191B2 (ja) | 形成外科における組織弁壊死の予防 | |
| CN110678166A (zh) | 增强非手术医学治疗的方法 | |
| JP7613776B2 (ja) | 経皮送達製剤 | |
| JPH06135829A (ja) | 血管内膜細胞過剰増殖疾患の予防および治療剤 | |
| TW201330871A (zh) | 局部產生一氧化氮的組合物和方法 | |
| MX2008012496A (es) | Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina. | |
| Kuczyńska et al. | The comparison of dexketoprofen and other painkilling medications (review from 2018 to 2021) | |
| MX2008012495A (es) | Formulaciones de dosis baja de diclofenaco y beta-ciclodextrina. | |
| BRPI0111142B1 (pt) | Use of derivatives of biguanide or of its pharmaceutically acceptable salts thereof for manufacture of a medicinal product having a healing effect | |
| JP2012255018A (ja) | 感覚器官的に許容されるイブプロフェン経口投与用製剤、該製剤の製法並びに使用法 | |
| Werre et al. | Isosorbide dinitrate in the treatment of anal fissure: a randomised, prospective, double blind, placebo‐controlled trial | |
| Sharma et al. | The effect of intravenous dexamethasone on intraoperative and early postoperative pain in lumbar spine surgery: a randomized double-blind placebo-controlled study | |
| AU2006252204B2 (en) | Prevention of Flap Necrosis in Plastic Surgery | |
| WO2014176417A1 (en) | Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system | |
| WO2003013548A1 (en) | Medical composition for external use for dermatosis | |
| KR101008052B1 (ko) | 경피흡수형 뇌 보호제 | |
| Lau et al. | Prospective randomized trial of pre-emptive analgesics following ambulatory inguinal hernia repair: intravenous ketorolac versusdiclofenac suppository. | |
| JP2007513983A (ja) | 壊死性腸炎のための治療 | |
| ES2267796T3 (es) | Uso de fibratos para la preparacion de un medicamento util en el tratamiento de insuficiencia cardiaca congestiva. | |
| Cashman | Non-steroidal anti-inflammatory drugs versus postoperative pain | |
| CN109562179A (zh) | N,n-双-2-巯基乙基间苯二甲酰胺的新用途 | |
| Khan et al. | Comparison of First Analgesic Demand in Post-Operative Period Among Diclofenac Group Versus Paracetamol Group | |
| Kristensen et al. | Relief of pain and trismus in patients treated with naproxen or acetylsalicylic acid after tonsillectomy | |
| Karale et al. | Study of intra operative haemodynamic stability of oral gabapentin to attenuate peri-operative pain | |
| Litvinova | Analysis of clinical efficacy and safety of intravenous use of diclofenac for the prevention of postoperative pain: current status and strategic aspect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |